The most talked about health care story of the month was the potential mega deal between pharma heavyweights Pfizer (NYSE: PFE) and AstraZeneca (NYSE: AZN). The $118 billion inversion deal, would have moved Pfizer to the U.K. for a lower tax rate, gained it a potential immuno-oncology blockbuster drug, and set the combined company up to reduce costs while bulking up potential divisions for divestment.
However, none of that will come to pass. Pfizer, despite an aggressive courtship and PR effort that included testifying in front of the U.K. Parliament, couldn't convince AstraZeneca management of the deals merits. Pfizer's failure to close has left investors with more questions than answers.
In this video, Motley Fool health care analysts David Williamson and Michael Douglass discuss why this deal was important for Pfizer and potential next moves for the big pharma. Will Pfizer reload and go hunting for another big pharma or will it focus inward to create value for shareholders? Watch and find out.
Top dividend stocks for the next decade
The smartest investors know that dividend stocks simply crush their non-dividend paying counterparts over the long term. That's beyond dispute. They also know that a well-constructed dividend portfolio creates wealth steadily, while still allowing you to sleep like a baby. Knowing how valuable such a portfolio might be, our top analysts put together a report on a group of high-yielding stocks that should be in any income investor's portfolio. To see our free report on these stocks, just click here now.
David Williamson owns shares of Pfizer. Michael Douglass has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.